Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited)

v3.22.1
Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Revenues, net $ 47,531,000 $ 15,271,000
Cost of revenues 18,854,000 6,344,000
Gross profit 28,677,000 8,927,000
Operating expenses:    
Diagnostic expenses 4,672,000 3,809,000
General and administration 7,824,000 3,782,000
Research and development 35,000 115,000
Total operating expenses 12,531,000 7,706,000
Income (loss) from operations 16,146,000 1,221,000
Interest income, net 73,000 87,000
Interest expense (233,000) (251,000)
Change in fair value of investment securities (76,000)
Income from operations before income taxes 15,910,000 1,057,000
Income tax expense (3,416,000)
Income from operations after income taxes 12,494,000 1,057,000
Net income 12,494,000 1,057,000
Other comprehensive loss:    
Unrealized gain (loss) on marketable debt securities 37,000 (11,000)
Total comprehensive income $ 12,531,000 $ 1,046,000
Earnings per share:    
Basic $ 0.81 $ 0.07
Diluted $ 0.68 $ 0.06
Weighted average common shares outstanding:    
Basic 15,486 14,563
Diluted 18,740 18,200